Poster Abstract Session:
247. New Antibiotics in Development
Saturday, October 29, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

.

Tracks: Adult ID

Presentations:
Zidebactam Phase 1 Single Ascending Dose and Crossover Study in Healthy Subjects
Ashima Bhatia, MD ; Mugdha Gupta, MBA ; Rakesh Chugh, MD
Posters
  • 2236 Poster ID week.pdf (197.6 kB)
  • In vitro Activity and Microbiological Efficacy of Gepotidacin (GSK2140944): A Phase II, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections
    Nicole Scangarella-Oman, MS ; Karen Ingraham, MS ; Courtney Tiffany, BS ; Caroline Perry, PhD ; Teri Ashton, PhD ; Etienne Dumont, MD ; Jianzhong Huang, PhD ; Linda Miller, PhD
    A Novel Non-Antibiotic Nitroglycerin Based Catheter Lock Solution for the Prevention of Intraluminal Central Venous Catheter Related Bloodstream Infections (CRBSI) in Cancer Patients
    Anne-Marie Chaftari, MD ; Ray Hachem, MD, FIDSA ; Ariel D. Szvalb, MD ; Mahnaz Taremi, MD, MPH ; Bruno Granwehr, MD ; George M. Viola, MD, MPH ; Amin Sapna, PharmD ; Andrew Assaf, MD ; Yazan Numan, MD ; Pankil Shah, MD, MSPH ; Edd Felix, BS ; Elizabeth Natividad, BSN ; Ying Jiang, MS ; Rebecca Slack, BA ; Ruth Reitzel, MS ; Joel Rosenblatt, PhD ; Elie Mouhayar, MD ; Issam Raad, MD, FIDSA, FSHEA
    Efficacy, Safety and Tolerability of Gepotidacin (GSK2140944) in Patients with Acute Bacterial Skin and Soft Structure Infections from a Phase II Randomized, Adaptive Design, Dose Ranging Study
    William O' Riordan, MD ; Courtney Tiffany, BS ; Nicole Scangarella-Oman, MS ; Caroline Perry, PhD ; Mohammad Hossain, PhD ; Teri Ashton, PhD ; Etienne Dumont, MD
    Utilizing a Clinical Utility Index in a Phase II, Randomized, Bayesian Response-Adaptive Design to Study the Efficacy and Safety of Gepotidacin (GSK2140944) in Patients with Acute Bacterial Skin and Skin Structure Infections
    Teri Ashton, PhD ; Ohad Amit, PhD ; Etienne Dumont, MD ; Nicole Scangarella-Oman, MS ; Mohammad Hossain, PhD ; Caroline Perry, PhD ; Mark Fitzgerald, PhD ; Kert Viele, PhD
    Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase Inhibitor ETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014
    Alita Miller, PhD ; Meredith Hackel, PhD, MPH ; Samuel Bouchillon, MD ; Boudewijn Dejonge, PhD ; Ruben Tommasi, PhD ; John Mueller, PhD
    The Staphylococcal-specific Antibiotic Debio 1450 Minimizes Disturbance to the Gut Microbiota in Mice
    Juliane Kuehn, PhD ; Frederick Wittke, MD ; Maryse Barbier, PhD ; Sophie Le Fresne, . ; Thomas Carton, . ; Sebastien Leuillet, . ; Francoise Le Vacon, . ; Gregoire Vuagniaux, PhD
    Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii
    John O'donnell, BS Biochemistry ; Alita Miller, PhD ; John Mueller, PhD ; Ruben Tommasi, PhD ; Harish Shankaran, PhD ; Douglas Ferguson, PhD
    Sulbactam combined with the Novel β-lactamase Inhibitor ETX2514 for the Treatment of Multidrug-resistant Acinetobacter baumannii Infections
    Sarah Mcleod, PhD ; Adam Shapiro, PhD ; Samir Moussa, PhD ; Nicole Carter, MS ; Michele Johnstone, MS ; Robert Mclaughlin, PhD ; Boudewijn Dejonge, PhD ; Ruben Tommasi, PhD ; John Mueller, PhD ; Alita Miller, PhD
    Discovery of a Tri-substituted Furan Antibacterial That Is More Active against Quinolone-resistant DNA Gyrase Than Wild-type
    Jianzhong Huang, PhD ; Carol Shen, MS ; Karen Ingraham, MS ; Lynn Mccloskey, BS ; Pan Chan, PhD ; Robert Stavenger, PhD
    Posters
  • ID Week 2016 poster_PDF.pdf (632.5 kB)
  • Potent and Sustained Activity of Novel THIOMAB™ Antibiotic Conjugate (TAC) against Staphylococcus aureus as Measured by Bioluminescence Imaging
    Chenguang Zhou, PhD ; Amos Baruch, PhD ; Saroja Ramanujan, PhD ; Thomas Pillow, PhD ; Meng Yang, PhD ; Fengxun Guo, MS ; Deming Xu, PhD ; Amrita Kamath, PhD
    Mechanism of Action of ELQ-316 Against Toxoplasma gondii: Evidence for Qi Site Inhibition of Cytochrome bc1.
    P. Holland Alday Jr., MD, PhD ; Igor Bruzal, PhD ; Sovitj Pou, PharmD ; Aaron Nilsen, PhD ; Michael K Riscoe, PhD ; Joseph Doggett, MD
    Modelling helps understanding reduction of mortality provided by DAV131A in a hamster model of moxifloxacin-induced Clostridium difficile colitis
    Charles Burdet, M.D., MPH ; Thu Thuy Nguyen, PhD ; Nathalie Saint-Lu, PhD ; Sakina Sayah-Jeanne, PhD ; Antoine Andremont, MD, PhD ; France Mentré, MD, PhD ; Jean De Gunzburg, PhD
    The Comparative Efficacy of Antibiotics against Experimental Clostridium septicum Infection
    Michael Aldape, PhD ; Clifford Bayer, BS ; Savannah Rice, BS ; Amy Bryant, PhD ; Dennis Stevens, MD, PhD

    CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.